All the following are true regarding HMG-CoA reductase inhibitors except (AIIMS Nov 2012)
|A||Simvastatin is extensively metabolized and pravastatin least|
|B||Fibrinogen levels are increased by pravastatin|
|C||Bioavailability is maximally modified when pravastatin is taken along with food|
|D||Simvastatin and lovastatin have maximal CNS accumulation|
a. The statins are the most effective and best-tolerated agents for treating dyslipidemia.
b. These drugs are competitive inhibitors of HMG-CoA reductase, which catalyzes an early, rate-limiting step in cholesterol biosynthesis.
c. Higher doses of more potent statins (atorvastatin and simvastatin) can also reduce triglyceride levels caused by elevated VLDL levels.
d. Clinical trails have clearly documented the efficacy and safety of simvastatin, pravastatin, and lovastatin in reducing fatal and nonfatal CHD events, strokes and total mortality.
e. Differences in solubility of the statins prompted speculation that the more lipid-soluble drugs might be more likely to penetrate the CNS.